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Key message and recommendations summary
LSE’s new health policy report Improving Access 
to Contraception (published on September 4th 
2017) reviews the development of contraception 
services for women in the UK, and offers an analysis 
of how further improvements in NHS (and where 
viable privately purchased) care and support should 
be pursued. This summary provides an overview of 
Improving Access to Contraception’s main findings 
and recommendations relating to the continuing 
need to improve NHS sexual and reproductive 
(SRH) health services and the role that extended 
community pharmacy based services could play in 
cost-effectively improving quality and outcomes.
Against a national background in which the 
conception rate amongst women aged 35 and over 
has doubled since 1990, while that for women aged 
20 and under has halved during the last decade 
alone, the report’s key messages include:
?? Ensuring that every child is wanted and born 
into an environment that has the material and 
emotional resources needed to care for her 
or him well is a vital public health goal for all 
societies. Failing to invest adequately in high 
quality, universally and conveniently accessible, 
public services capable of providing women 
with contraception tailored to meet their needs 
as well as possible would be a false economy. 
The available evidence indicates that in Britain 
every £1 spent appropriately on contraception 
generates benefits worth over £10.
?? Preventing and effectively treating sexually 
transmitted infections (STIs) such as HIV, 
gonorrhoea, genital warts and chlamydia (which 
alone accounted for just under half of all new STIs 
reported in England in 2015) is a separate, but 
also important, public health objective. STIs occur 
most frequently in the under 25 age group. But 
older individuals are not immune to them. In the 
case of syphilis, for instance, infection rates are 
currently highest amongst older sexually active 
people, particularly men who have sex with men.
?? The UK nations have a relatively good record in the 
provision of sexual and reproductive health (SRH) 
services. However, despite recent advances the 
rates of unwanted conceptions amongst younger 
women in their teens and early twenties are still 
higher in Britain than in many other western 
European nations. There are also concerns that 
a proportion of older women are not receiving 
good quality contraception support, and that GP 
provision of long acting reversible contraceptives 
(LARCs) such as Intra-Uterine Devices (IUDs) is 
inadequately funded. Older women may also be 
disadvantaged when seeking treatment for STIs.
?? Previously unpublished evidence presented in 
Improving Access to Contraception shows that in 
England one woman in every seven strongly believes 
that accessing contraception could be made more 
convenient for them. Other sources (including the 
National Survey of Sexual Attitudes and Lifestyles 
– NATSAL) indicate that at any one time about one 
woman in every ten is dissatisfied with her current 
method of contraception. Dissatisfaction with 
services and contraceptive methods is linked to a 
raised risk of unwanted conceptions.
?? The new data presented in Improving Access 
to Contraception also shows that over half the 
female population aged between 18 and 50 
agrees with the statement ‘women should be 
able to obtain items like The Pill directly from their 
pharmacist, rather than after seeing a doctor or a 
nurse, if that is what they prefer.’
?? Areas where better access to contraception 
via extended community pharmacy based 
provision could enhance outcomes range from 
enhancing the availability of supportive, non-
judgemental, access to contraception of all 
types for ‘adolescent’/younger women to further 
encouraging the effective use of emergency 
contraception (including that of IUDs, as well 
as hormonal methods/EHC) and increasing the 
uptake of LARCs amongst women of all ages.
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?? There is evidence from the Kings Fund that in 
England spending on sexual and reproductive 
health services (including the provision of LARCs 
by GPs and practice nurses) funded via Local 
Authority public health budgets will fall by about 
5 per cent in 2017/18 as compared to the 
previous year. This may impede efforts to further 
improve services for young women at high risk 
of unwanted conceptions (in total about a half 
of all conceptions are still unplanned in the UK) 
and older women who are not satisfied with their 
current contraception.
?? The 2012 NHS reforms fragmented SRH service 
commissioning in England. Assuring a coherent 
strategic approach, aimed at maintaining public 
confidence in the NHS and optimising the 
contributions of all the health professionals in 
primary care (who presently meet 80 per cent 
of all women’s contraception needs) and other 
health service and voluntary sector facilities 
should be recognised as an important priority.
What does the available evidence 
show about community pharmacy 
based access to contraception?
Community pharmacists have long been involved 
in supplying contraceptives such as condoms, as 
well as products such as pregnancy testing kits and 
folic acid pills. Over and above their established 
role in the emergency hormonal contraception 
(EHC) context, Improving Access to Contraception 
describes multiple pilot schemes that have involved 
NHS community pharmacists in recommending 
and providing oral contraception pills (OCPs) and 
other implantable or injectable contraceptives.
Together with US evidence and wider global 
experience (in most of the world OCPs are not 
restricted to prescription only supply) these initiatives 
show that NHS community pharmacists can safely 
provide contraception services. If necessary they can 
also make referrals to GPs or hospital doctors in order 
for women to obtain IUDs or specialist STI care.
The ongoing development of computer based 
patient record systems and clinical decision aids will 
progressively increase the ability of pharmacy based 
health professionals to provide high quality health 
care to people who prefer to use them, in ways that 
are consistent with requirements for comprehensive 
record keeping. So too will the continuing evolution 
of near patient diagnostic testing and health status 
monitoring technologies.
What advantages do community 
pharmacy based services offer to 
users and the wider public?
Extended pharmacy based contraception services 
can for those women who choose them in preference 
to other options offer increased access and greater 
convenience, along with the maintenance of high 
standards of clinical care. Appropriately designed, 
pharmacy based services will enable GPs and 
practice nurses to focus more on those services 
they are best able to provide, such as IUD and 
IUS (intra-uterine system) insertions. Extended 
community pharmacy care could also offer the NHS 
greater overall economic efficiency.
Across all areas of health care, reducing pressures 
on hospital facilities demands increased primary 
care capacity and activity levels. This requires using 
existing resources like community pharmacies 
to provide as much good quality health care as 
possible, in order to allow GPs and their practice 
colleagues more time for tasks they are uniquely 
qualified to undertake.
What barriers to change will need to 
be overcome?
Barriers to overcome include a lack of strategic insight 
into the long term economic and social value of new 
models of health care that fully recognise the abilities 
of community pharmacy based and other non-
medical health professionals to provide high quality 
health care. Even within community pharmacy itself 
some pharmacists do not wish to move away from 
their traditional dispensing role. However, Improving 
Access to Contraception concludes that significant 
change will be inevitable as new dispensing and 
related medicines supply technologies are introduced 
and shortages of doctors and nurses persist, or are 
increased, as a result of events such as Brexit and 
wider global trends.
Some doctors and service managers also 
oppose extending pharmacy’s part in providing 
contraception. Fears that declining public health 
resources may be diverted from specialist SRH 
centres and GP practices are a current cause of 
concern for some observers. Policy makers should 
seek to ensure that false economies, ‘silo budgets’ 
and unnecessarily monopolistic practices do not 
create counter-productive rigidities within the NHS. 
Failure to do so could ultimately undermine the 
affordability and quality of publicly supported health 
care in not only the SRH context but more generally.
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What policy and practice questions 
still need to be resolved?
In addition to questions about how extended 
pharmacy based contraceptive care should be 
funded, key issues yet to be resolved include 
whether it would be in the public’s interest to 
make progestogen only pills (POPs or ‘mini-pills’) 
and combined oral hormonal contraceptives 
(COPs) Pharmacy as opposed to Prescription 
Only medicines and how a more fully informed 
population-wide understanding of sexual and 
reproductive health issues might best be fostered.
Improving Access to Contraception argues that 
one way forward could, with the involvement of the 
Royal Pharmaceutical Society and/or other bodies, 
be to organise a consultation aimed at forming 
a strengthened consensus on how community 
pharmacists should develop their roles beyond that 
of providing EHC and advice about medicines taking 
and using products such as pregnancy tests. Over 
and above determining ways forward that combine 
respect for service user choice and privacy with 
a recognition of the value of well integrated SRH 
and wider health records, the questions such a 
consultation could address include:
?? ought all NHS pharmacies offer a full extended 
contraceptive service, or would it be better for a 
limited number to provide higher level support in 
any particular locality?
?? will future progress towards developing better 
integrated contraception and other SRH 
services best be achieved locally through health 
professionals like GPs, practice and community 
nurses and community pharmacists working 
together in ‘primary care homes’ or similar 
organisations, or is a new nation-wide initiative 
required?
Conclusions
The analysis provided in Improving Access to 
Contraception indicates that both local initiatives 
and consolidated national strategies are needed. 
There is a powerful case for building on pilot 
projects that have demonstrated the potential of 
NHS community pharmacies to provide enhanced 
access to contraception and other SRH services in 
all four UK nations.
Community pharmacists can also play a wider role 
on primary health care more generally. However, in 
the final analysis no single group can assure system-
wide excellence. Achieving the best affordable 
health outcomes will require complementary efforts 
aimed at meeting service users’ needs on the 
parts of all those involved. Key groups involved 
in contraception include not hospital based 
medical consultants and their specialist nursing 
and pharmacist colleagues together with GPs 
and practice nurses, but also other NHS, LA and 
voluntary organisation personnel. The latter include 
midwives, health visitors and social workers.
To strengthen their role as health care professionals 
community pharmacists must demonstrate their 
ability to work constructively with service users and 
other service providers. Pharmacy as a profession 
should also seek to communicate to decision 
makers why improving access to contraception 
and other forms of sexual and reproductive health 
care remains central to protecting the health of the 
nation.
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